186 related articles for article (PubMed ID: 37067993)
1. TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase.
Chandhasin C; Dang V; Perabo F; Del Rosario J; Chen YK; Filvaroff E; Stafford JA; Clarke M
Anticancer Drugs; 2023 Nov; 34(10):1122-1131. PubMed ID: 37067993
[TBL] [Abstract][Full Text] [Related]
2. Advances in histone demethylase KDM4 as cancer therapeutic targets.
Lee DH; Kim GW; Jeon YH; Yoo J; Lee SW; Kwon SH
FASEB J; 2020 Mar; 34(3):3461-3484. PubMed ID: 31961018
[TBL] [Abstract][Full Text] [Related]
3. KDM4 Demethylases: Structure, Function, and Inhibitors.
Jiang Y; Liu L; Yang ZQ
Adv Exp Med Biol; 2023; 1433():87-111. PubMed ID: 37751137
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Novel Benzimidazole Pyrazolone Scaffold That Inhibits KDM4 Lysine Demethylases and Reduces Proliferation of Prostate Cancer Cells.
Carter DM; Specker E; Przygodda J; Neuenschwander M; von Kries JP; Heinemann U; Nazaré M; Gohlke U
SLAS Discov; 2017 Aug; 22(7):801-812. PubMed ID: 28346812
[TBL] [Abstract][Full Text] [Related]
5. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.
Berry WL; Janknecht R
Cancer Res; 2013 May; 73(10):2936-42. PubMed ID: 23644528
[TBL] [Abstract][Full Text] [Related]
6. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.
Chin YW; Han SY
Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances with KDM4 Inhibitors and Potential Applications.
Wu Q; Young B; Wang Y; Davidoff AM; Rankovic Z; Yang J
J Med Chem; 2022 Jul; 65(14):9564-9579. PubMed ID: 35838529
[TBL] [Abstract][Full Text] [Related]
8. KDM4 inhibitor SD49-7 attenuates leukemia stem cell
Li Y; Wang C; Gao H; Gu J; Zhang Y; Zhang Y; Xie M; Cheng X; Yang M; Zhang W; Li Y; He M; Xu H; Zhang H; Ji Q; Ma T; Ding S; Zhao Y; Gao Y
Theranostics; 2022; 12(11):4922-4934. PubMed ID: 35836814
[No Abstract] [Full Text] [Related]
9. The histone demethylase Kdm4 suppresses activation of hepatic stellate cell by inducing MiR-29 transcription.
Kong M; Wu J; Fan Z; Chen B; Wu T; Xu Y
Biochem Biophys Res Commun; 2019 Jun; 514(1):16-23. PubMed ID: 31014673
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression.
Young LC; Hendzel MJ
Biochem Cell Biol; 2013 Dec; 91(6):369-77. PubMed ID: 24219278
[TBL] [Abstract][Full Text] [Related]
11. In-silico guided chemical exploration of KDM4A fragments hits.
Lombino J; Vallone R; Cimino M; Gulotta MR; De Simone G; Morando MA; Sabbatella R; Di Martino S; Fogazza M; Sarno F; Coronnello C; De Rosa M; Cipollina C; Altucci L; Perricone U; Alfano C
Clin Epigenetics; 2023 Dec; 15(1):197. PubMed ID: 38129913
[TBL] [Abstract][Full Text] [Related]
12. Unravelling KDM4 histone demethylase inhibitors for cancer therapy.
Baby S; Gurukkala Valapil D; Shankaraiah N
Drug Discov Today; 2021 Aug; 26(8):1841-1856. PubMed ID: 34051367
[TBL] [Abstract][Full Text] [Related]
13. The KDM4/JMJD2 histone demethylases are required for hematopoietic stem cell maintenance.
Agger K; Nishimura K; Miyagi S; Messling JE; Rasmussen KD; Helin K
Blood; 2019 Oct; 134(14):1154-1158. PubMed ID: 31434704
[TBL] [Abstract][Full Text] [Related]
14. Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family.
Hillringhaus L; Yue WW; Rose NR; Ng SS; Gileadi C; Loenarz C; Bello SH; Bray JE; Schofield CJ; Oppermann U
J Biol Chem; 2011 Dec; 286(48):41616-41625. PubMed ID: 21914792
[TBL] [Abstract][Full Text] [Related]
15. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
Ye Q; Holowatyj A; Wu J; Liu H; Zhang L; Suzuki T; Yang ZQ
Am J Cancer Res; 2015; 5(4):1519-30. PubMed ID: 26101715
[TBL] [Abstract][Full Text] [Related]
16. Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential.
Labbé RM; Holowatyj A; Yang ZQ
Am J Transl Res; 2013; 6(1):1-15. PubMed ID: 24349617
[TBL] [Abstract][Full Text] [Related]
17. Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells.
Agger K; Miyagi S; Pedersen MT; Kooistra SM; Johansen JV; Helin K
Genes Dev; 2016 Jun; 30(11):1278-88. PubMed ID: 27257215
[TBL] [Abstract][Full Text] [Related]
18. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
19. Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development.
Pedersen MT; Kooistra SM; Radzisheuskaya A; Laugesen A; Johansen JV; Hayward DG; Nilsson J; Agger K; Helin K
EMBO J; 2016 Jul; 35(14):1550-64. PubMed ID: 27266524
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
Duan L; Perez RE; Calhoun S; Maki CG
Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
